

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
19 August 2004 (19.08.2004)

PCT

(10) International Publication Number
WO 2004/069228 A2

(51) International Patent Classification⁷: **A61K 9/22**,
9/32, 31/137

(21) International Application Number:
PCT/IS2004/000003

(22) International Filing Date: 9 February 2004 (09.02.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
6710 7 February 2003 (07.02.2003) IS
7143 5 February 2004 (05.02.2004) IS

(71) Applicant (for all designated States except US): **OMEGA FARMA EHF.** [IS/IS]; Skutuvogi 1H, IS-104 Reykjavik (IS).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **JOHANNSSON, Fjalar** [IS/IS]; Hvassaleiti 14, IS-103 Reykjavik (IS).
ARNASON, Birkir [IS/IS]; Kaplaskjolsvegi 85, IS-107 Reykjavik (IS).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM,

AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declaration under Rule 4.17:

— of inventorship (Rule 4.17(iv)) for US only

Published:

— without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: SUSTAINED RELEASE FORMULATIONS OF VENLAFAXINE

(57) Abstract: The present invention relates to sustained release tablet formulations of venlafaxine. Kollidon SR proved to be an excellent sustained release agent for venlafaxine, that is an extremely soluble drug.

WO 2004/069228 A2

Sustained Release Formulations of Venlafaxine

FIELD OF THE INVENTION

5

The present invention relates to sustained release tablet formulations of venlafaxine.

TECHNICAL BACKGROUND AND PRIOR ART

10

Venlafaxine, (+/-)-[α -[(dimethylamino)methyl]-p-methoxybenzyl]cyclohexanol, is a phenylethylamine derivative which facilitates neurotransmission in the brain by blocking presynaptic reuptake of serotonin and noradrenaline for use in treating depression. See for example Holliday and Benfield, Venlafaxine, a review of its pharmacology and therapeutic potential in depression, Drugs, 15 Vol. 49, No. 2, 1995, pp 280-294.

US patent 4,535,186 describes venlafaxine and its acid additional salts.

20 The preparation of useful sustained release formulations of venlafaxine hydrochloride is complicated because venlafaxine HCl is very water soluble. The advantage of sustained release tablets compared to conventional tablets is that the frequency of dosage administration is reduced. Sustained release formulations can further have the advantage of inducing less side effects than 25 conventional tablets, because the blood plasma levels of the active compound increase more slowly.

WO 9427589 concerns controlled-release dosage forms comprising venlafaxine and polymers selected from poly(alkylene oxide) polymer, 30 cellulose polymer and maltodextrin polymer.

WO 99/22724 (EP 1028718) relates to extended release spheroid cores of venlafaxine hydrochloride. The cores are prepared by means of microcrystalline cellulose without the addition of

hydroxypropylmethylcellulose. Furthermore, ethylcellulose is used as sustained release coating agent on the core in this formulation.

Sustained release tablets of venlafaxine hydrochloride are discussed in
5 Makhija and Vavia, Once daily sustained release tablets of venlafaxine, a novel antidepressant, European Journal of Pharmaceutics and Biopharmaceutics, Vol. 54, No. 1, July 2002, pp 9-15. The article relates to matrix system based on swellable as well as non-swellable polymers. The polymers studied are hydroxypropylmethylcellulose, cellulose acetate,
10 Eudragit RSPO and ethylcellulose.

SUMMARY OF THE INVENTION

In an attempt to prepare a suitable sustained release tablet of venlafaxine
15 numerous sustained release agents were tried, povidone (e.g. Kollidone), hydrogenated vegetable oil (e.g. Lubritab), polyethylene glycol (e.g. Macrogol), glyceril behenate (e.g. Compritol), polymethacrylates (e.g. Eudragit), hydroxypropylmethylcellulose (e.g. Methocel) and glyceryl palmitostearate (e.g. Precirol).
20

It was discovered that useful formulations of venlafaxine can be produced by use of a mixture of povidone and polyvinylacetate known as Kollidone SR.

Kollidon SR is used in various applications including preparing sustained
25 release pharmaceutical compositions, as described in the technical and patent literature. For example, EP 0 231 826 B1 describes sustained release tablet containing theophylline as the active ingredient.

The properties of Kollidone SR are described in V. Bühler, Kollidon®,
30 Polyvinylpyrrolidone for the pharmaceutical industry, 233 - 249, BASF, Ludwigshafen 2001.

Kollidone SR consists mainly of two polymers, povidone and polyvinyl acetate. The povidone part is water soluble but the polyvinyl acetate is water-insoluble.

When a tablet comprising Kollidone SR is immersed in a water solution the water soluble polymer dissolves and passages are formed in the tablet. The active ingredient will then diffuse through the passages.

- 5 Although Kollidone SR is a known sustained release agent, the inventors were surprised to find that it was so suitable agent for venlafaxine because of the high solubility of the active material.

10 However, the dissolution profile of uncoated tablets that contained Kollidone SR as the only sustained-release agent showed a faster release in the beginning than was intended. In a single dose pharmacokinetic study of these tablets the C_{max} was slightly higher in the beginning than was anticipated.

15 In an attempt to further control the initial rate of release of venlafaxine from the tablets, several types of film materials were tested and polymethacrylates proved to be suitable and several types of this film material were extensively tested. Coating the tablets with a film that contained polymethacrylates proved to be surprisingly effective for the sustained release tablet of venlafaxine.

20 The polymethacrylates that were tested are mixtures of polyethyl acrylate and polymethyl methacrylate and they optionally also include trimethylammonioethyl methacrylate chloride. The trade names for the tested polymethacrylates are Eudragit RS, Eudragit RL and Eudragit NL.

25 By coating the tablets with a film containing Eudragit SR 30 D, the C_{max} fitted intended criteria.

30 Conventional hydroxypropylmethylcellulose (HPMC) based coatings do not affect the dissolution rate of sustained release tablets, since they dissolve too quickly *in vivo*.

Properties of polymethacrylates are described in A. H. Kibbe, Handbook of pharmaceutical excipients, 401 – 406, American Pharmaceutical Association, Washington, and Pharmaceutical Press, London, 2000.

Eudragit RS is a water insoluble, swellable film-former based on neutral methacrylic acid esters with a small proportion of trimethylaminoethyl methacrylate chloride. The ratio is 1:40 trimethylaminoethyl methacrylate chloride : methacrylic acid esters.

The quaternary ammonium groups determine the swellability of the films and their permeability to water, dissolved salts and medicinal substances. The small amount in the Eudragit RS result in the properties that it swells less than comparable Eudragit film formers, and is only slightly permeable to active ingredients.

BRIEF DESCRIPTION OF FIGURES

Figure 1 shows the effect of increasing amount of Kollidone RS on the dissolution rate of venlafaxine HCl.


Figure 2 shows the effect of increasing the hardness of the tablets on the dissolution profile of venlafaxine HCl.

Figure 3 shows the dissolution profiles of venlafaxine sustained release tablets in two different media, water and 0.01M HCl. The dissolution profiles are independent of the pH.

Figure 4 shows the dissolution profiles of uncoated tablets and tablets coated with a film containing Eudragit RS 30 D. The amount of the film on the tablet surface affects the dissolution rate.

DETAILED DESCRIPTION

The invention provides a sustained release pharmaceutical formulation comprising pharmaceutically effective amount of venlafaxine or an acid addition salt thereof,



a sustained release agent selected from sustained release agent selected from povidone, a mixture of povidone and polyvinyl acetate, hydrogenated vegetable oil, polyethylene glycol, glyceril behenate and glyceril palmitostearate; and a lubricant.

The pharmaceutical formulation of the present invention comprises:

- a) 15 - 40% w/w of venlafaxine HCl;
 - b) 50 - 85% w/w of the sustained release agent; and
 - c) 0.5 - 5.0% w/w of lubricant
- and optionally a filler material and glidant.

The sustained release agent may suitably be selected from povidone (e.g. Kollidone), a mixture of povidone and polyvinyl acetate (e.g. Kollidone SR), hydrogenated vegetable oil (e.g. Lubritab), polyethylene glycol (e.g. Macrogol), glyceril behenate (e.g. Compritol), polymethacrylates (e.g. Eudragit), hydroxypropylmethylcellulose (e.g. Methocel) and glyceryl palmitostearate (e.g. Precirol).

The Kollidone SR was found to be especially suitable in controlling the release of venlafaxine. It was found that the dissolution profiles for the tablets depend on the amount of the Kollidone SR. Furthermore, it was found that the hardness of the tablets could be used to adjust the rate of the release of

venlafaxine to the preferred dissolution profile. The hardness factor was especially surprising since usually the properties of Kollidone SR are not affected by the hardness of the tablets.

- 5 The lubricant is selected from magnesium stearate, hydrogenated vegetable oil, glyceryl dibehenate and sodium fumaric acid. Magnesium stearate is preferred.

- 10 For a sustained release tablet formulation containing 37.5 mg venlafaxine, the preferable amount of venlafaxine HCl is 19 - 25% w/w, the preferable amount of Kollidone SR is 55-70% w/w and the preferable amount of magnesium stearate is 2-4% w/w.

- 15 For a sustained release tablet formulation containing 75 mg venlafaxine, the preferable amount of venlafaxine HCl is 19 - 25% w/w, the preferable amount of Kollidone SR is 55-70% w/w and the preferable amount of magnesium stearate is 2-4% w/w.

- 20 For a sustained release tablet formulation containing 150 mg venlafaxine, the preferable amount of venlafaxine HCl is 24-30% w/w, the preferable amount of Kollidone SR is 50-70% w/w and the preferable amount of magnesium stearate is 2-4% w/w.

- 25 In one embodiment the tablet is film-coated.

The film coated tablet formulation of the present invention comprises:

- a) 15 - 40% w/w of venlafaxine;
 - b) 50 - 85% w/w of the sustained release agent;
 - c) 0.5 - 5.0% w/w of lubricant;
- 30 and optionally a filler material and/or glidant,
wherein the tablet is coated with a film wherein the film-forming material is selected from polymethacrylates.

Several film forming types of polymethacrylates were evaluated, Eudragit NE, Eudragit RL, Eudragit SR 30 D and Eudragit RS powder. Eudragit SR 30 D gave the best result.

- 5 The coating was performed by conventional pan spray coating process using solution containing the Eudragit SR 30 D (30% dispersion in water), titanium dioxide, talc, polyethylene glycol and purified water.

10 The time used in the coating process affects the amount of the film on the tablet surface. The amount of the film corresponding to 0.5-3.0% w/w, more preferably 1.0-2.0% w/w showed the most suitable dissolution profile for intended use as a sustained release pharmaceutical.

15 The coating solution includes 15-80 % w/w Eudragit RS 30 D, 0.5-10 % w/w titanium dioxide, 0.5-15 % w/w talc, 0.5-10 % w/w polyethylene glycol and 00-85 % w/w purified water, preferably 30-70 % w/w Eudragit RS 30 D, 1.5-6 % w/w titanium dioxide, 2-8 % w/w talc, 1.5-5 % w/w polyethylene glycol and 25-60 % w/w purified water, more preferably 45-60 % w/w Eudragit RS 30 D, 2-3 % w/w titanium dioxide, 3.5-5 % w/w talc, 1-3 % w/w polyethylene glycol and 20 30-50 % w/w purified water and most preferably 52-54 % w/w Eudragit RS 30 D, 2-3 % w/w titanium dioxide, 4-5 % w/w talc, 1-3 % w/w polyethylene glycol and 35-43 % w/w purified water.

25 The polyethylene glycol is preferably Macrogol 6000.

Dissolution of venlafaxine can also be adjusted by use of insoluble fillers such as calcium phosphate and microcrystalline cellulose. Calcium hydrogen phosphate dihydrate is preferred.

- 30 Optionally the formulations include glidants such as silica colloid anhydrate.

The dissolution profiles of the sustained release formulation are independent of the pH of the dissolution medium.

EXAMPLES

The following examples are merely illustrative of the present invention and they should not be considered as limiting the scope of the invention.

5

Example 1

The following materials were combined by wet granulation to produce 37.5 mg venlafaxine sustained release tablets

10

Venlafaxine HCl	42.5	mg
Kollidone SR	127.5	mg
Magnesium stearate	5	mg

15 Example 2

The following materials were combined by wet granulation to produce 75 mg venlafaxine sustained release tablets:

20	Venlafaxine HCl	85	mg
	Kollidone SR	255	mg
	Magnesium stearate	10	mg

Example 3

25

The following materials were combined by wet granulation to produce 150 mg venlafaxine sustained release tablets:

	Venlafaxine HCl	170	mg
30	Kollidone SR	400	mg
	Magnesium stearate	20	mg

Example 4

Dissolution profiles of slow release tablets prepared by the inventors.

5 Dissolution profiles for compositions that include relatively different amounts of kollidone SR.

Batch No	17	18	19	20
Tablets	Round tablets	Round tablets	Round tablets	Round tablets
	mg	mg	mg	mg
Venlafaxine HCl	42.5	42.5	42.5	42.5
Kollidone	127.5	152.5	192.5	252.5
Magnesium stearate	5.0	5.0	5.0	5.0
Total	175	195	240	300

Dissolution profiles for tablets having different amount of Kollidon SR
but the same amount of venlafaxine HCl and magnesium stearate

Time	Batch No.17	Batch No. 18	Batch No. 19	Batch No.20
min	% dissolved mean of 6 tablets	% dissolved mean of 6 tablets	% dissolved mean of 6 tablets	% dissolved mean of 6 tablets
0	0.3	0.0	0.0	0.0
30	24.1	24.6	20.5	16.2
60	32.5	32.9	27.5	22.5
120	42.1	42.0	35.2	29.4
180	48.5	47.8	40.2	33.8
240	53.5	52.6	44.0	37.3
300	58.0	56.9	47.1	40.0
360	62.1	60.7	50.0	42.5
420	65.8	64.1	52.9	44.9
480	69.0	67.2	55.4	47.1
540	72.1	70.0	57.8	49.2
600	74.6	72.6	60.2	51.1
660	76.9	74.8	62.2	53.1
720	79.0	76.8	64.2	55.1
780	80.9	78.5	66.2	57.0
840	82.4	80.2	68.0	58.7
900	84.1	81.7	69.6	60.5
960	85.2	82.9	71.3	61.9
1020	86.5	84.1	72.7	63.3
1080	87.5	85.2	74.0	64.7
1140	88.3	86.1	75.3	65.8
1200	89.0	86.9	76.6	67.0
1260	89.7	87.6	77.7	68.0
1320	90.3	88.4	78.9	69.0
1380	90.7	89.0	79.8	69.9
1440	91.1	89.5	80.8	70.9

- 5 Figure 1 shows the effect of increasing amount of Kollidone SR on the dissolution rate of venlafaxine HCl

Example 5

Dissolution profiles for tablets that include the same amount of Kollidone SR but the hardness of the tablets is different.

Time	Batch No. 17 Hardness 40N	Batch No. 17 Hardness 90N	Batch No. 17 Hardness 9 173N
<i>min</i>	% dissolved mean of 6 tablets	% dissolved mean of 6 tablets	% dissolved mean of 6 tablets
0	0	0	0
30	27.8	29.3	27.1
60	38	39.6	36.2
120	50.6	51.4	46.3
180	60.7	59.8	53
240	69	66.8	58.3
300	75.9	73	63
360	81.8	78.5	67.3
420	86.4	83.1	71.1
480	89.9	87.1	74.4
540	92.5	90.5	77.4
600	94.4	93.2	80.1
660	95.6	95.5	82.4
720	96.7	97.4	84.5
780	97.5	98.9	86.4
840	98	100	87.9
900	98.4	101	89.4
960	98.9	101.6	90.7
1020	99.3	102.2	91.9
1080	99.6	102.8	92.9
1140	100	103.1	93.7
1200	100.2	103.5	94.4
1260	100.6	103.9	95
1320	100.9	104.2	95.5
1380	101.1	104.5	96.1
1440	101.4	104.7	96.5

5

Figure 2 shows the effect of increasing the hardness of the tablets on the dissolution profile of venlafaxine 37.5 mg sustained release tablets

Example 6

Dissolution profiles of Venlafaxine sustained release tablets (same batch) are independent of the pH of the dissolution medium as shown in following table.

5

Hours	% Dissolved	% Dissolved
	Batch 14-0.01NHCl Mean of 6 tablets	Batch-14-water Mean of 6 tablets
0	0.0	0.0
1	27.2	27.5
2	36.8	37.2
3	43.5	43.8
4	48.7	48.9
5	53.1	53.3
6	57.1	57.2
7	60.8	60.8
8	64.2	64.2
9	67.3	67.3
10	70.3	70.2
11	73.0	72.9
12	75.5	75.3
13	77.8	77.6
14	79.9	79.8
15	81.9	81.8
20	89.8	89.7
24	94.3	94.2

Figure 3 shows the dissolution profiles.

10 Example 7

75 mg sustained release venlafaxine tablets were prepared by combining the following materials by wet granulation:

15	Venlafaxine HCl	22% w/w
	Kollidone SR	66.3% w/w
	Magnesium stearate	2.6% w/w
	Calcium hydrogen phosphate dihydrate	8.3% w/w
	Silica colloid anhydrate	0.8% w/w

20

The tablets were coated with Eudragit RS 30 D for different periods of time, resulting in 0.7% w/w film/tablet, 1.0% w/w film/tablet, 1.4% w/w film/tablet and 3.0% w/w film/tablet or not coated at all, for comparison in a dissolution test.

5

The coating liquid includes:

	Eudragit RS 30 D	53.00% w/w
	Titanium dioxide	2.21% w/w
	Talc	4.42% w/w
10	Macrogol 6000	1.90% w/w
	Purified water	38.47% w/w

Dissolution profiles of uncoated tablets and tablets with different amount of coating.

Time	Uncoated	Coating	Coating	Coating	Coating
[min]	%	0.7% w/w	1.0% w/w	1.4% w/w	3.0%w/w
dissolved	dissolved	%	%	%	%
0	0.0	0.0	0.0	0.0	0.0
30	21.0	18.7	13.4	10.7	3.1
60	29.9	26.9	21.1	18.5	8.9
120	40.7	37.7	31.2	28.0	20.2
180	48.5	45.3	38.7	34.9	27.7
240	54.5	51.3	44.7	40.5	33.3
300	59.8	56.4	49.7	45.3	38.0
360	64.3	60.8	54.2	49.6	42.2
420	68.4	64.8	58.2	53.4	46.2
480	72.1	68.3	61.9	57.1	49.8
540	75.5	71.6	65.3	60.4	53.1
600	78.5	74.6	68.5	63.5	56.3
660	81.2	77.2	71.4	66.4	59.2
720	83.6	79.6	74.1	69.0	61.9
780	85.7	81.8	76.7	71.5	64.4
840	87.5	83.7	78.9	73.8	66.8
900	89.2	85.4	80.9	75.9	69.0
960	90.6	87.0	82.8	78.0	71.2
1020	91.9	88.3	84.5	79.9	73.1
1080	93.0	89.6	86.0	81.8	74.9
1140	94.4	90.6	87.4	83.5	76.7
1200	95.0	91.6	88.6	84.9	78.3
1260	95.8	92.5	89.7	85.6	79.8
1320	96.5	93.2	90.7	86.8	81.2
1380	97.1	93.9	91.6	87.9	82.5
1440	97.6	94.5	92.5	88.9	83.8

15 Figure 4 shows the dissolution profiles.

Examples 1-3 show typical compositions of venlafaxine HCl, Kollidone SR and magnesium stearate.

Example 4 shows different dissolution profiles for various concentrations of Kollidon SR.

- 5 Example 5 shows different dissolution profiles for identical compositions with various hardness of tablets.

Example 6 shows that the dissolution profiles are independent of the pH.

Example 7 shows the dissolution profiles of coated and uncoated tablets.

10

By using Kollidone SR it was possible to adjust the dissolution profile of venlafaxine to a satisfactory level by changing the amount of Kollidone SR and the hardness of the tablets. By further employing Eudragit RS 30 D as a coating agent the C_{\max} fits the intended criteria.

15

CLAIMS

1. A sustained release tablet formulation comprising:
 - a) pharmaceutical effective amount of venlafaxine or an acid addition salt thereof;
 - b) a sustained release agent selected from povidone, a mixture of povidone and polyvinyl acetate, hydrogenated vegetable oil, polyethylene glycol, glyceril behenate and glyceril palmitostearate; and
 - c) a lubricant.
- 10 optionally in combination with a filling material and/or other excipients.
2. The sustained release tablet formulation of claim 1, comprising:
 - a) 15 - 30% w/w of venlafaxine HCl;
 - b) 50 - 85% w/w of a sustained release agent selected from povidone,
 - 15 a mixture of povidone and polyvinyl acetate, hydrogenated vegetable oil, polyethylene glycol, glyceril behenate and glyceril palmitostearate; and
 - c) 0.5 - 5.0% w/w of a lubricant.
- optionally in combination with a filling material and/or other excipients.
- 20 3. The sustained release tablet formulation of claim 1 or claim 2, wherein the sustained release agent is a mixture of povidone and polyvinyl acetate.
4. The sustained release tablet formulation of claim 3, wherein the sustained release agent is Kollidone SR.
- 25 5. The sustained release tablet formulation of claim 1 or claim 2, wherein the lubricant is selected from magnesium stearate, hydrogenated vegetable oil, glyceryl dibehenate and sodium fumaric acid.
- 30 6. The sustained release tablet formulation of claim 4, wherein the lubricant is magnesium stearate
7. The formulation of claim 1 or claim 2, which comprises venlafaxine HCl, Kollidone SR and magnesium stearate.

8. The sustained release tablet formulation of any of claims 1 to 7 containing 37.5 mg venlafaxine, wherein the amount of venlafaxine HCl is 19 - 25% w/w, the amount of Kollidone SR is 55-70% w/w and the amount of magnesium stearate is 2-4% w/w.

9. The sustained release tablet formulation of any of claims 1 to 8 containing 75 mg venlafaxine, wherein the amount of venlafaxine HCl is 19 - 25% w/w, the amount of Kollidone SR is 55-70% w/w and the amount of magnesium stearate is 2-4% w/w.

10. The sustained release tablet formulation of any of claims 1 to 9 containing 150 mg venlafaxine, wherein the amount of venlafaxine HCl is 24-30% w/w, the amount of Kollidone SR is 50-70% w/w and the amount of magnesium stearate is 2-4% w/w.

11. The sustained release tablet formulation of any of claims 1 to 10 additionally including filling material selected from calcium phosphate and microcrystalline cellulose.

12. The sustained release tablet formulation of claims 11 wherein the filling material is calcium hydrogen phosphate dihydrate.

13. The sustained release tablet formulation of any of claims 1 to 12 additionally including silica colloid anhydrate.

14. The sustained release tablet formulation of any of claims 1 to 13 wherein the tablet is film coated.

15. The sustained release tablet formulation of claim 14, wherein the film coating comprises polymethacrylate.

16. The sustained release tablet formulation of claim 15, wherein the polymethacrylate is selected from Eudragit RS, Eudragit RL and Eudragit NE.

17. The sustained release tablet formulation of claim 16, wherein the polymethacrylate is Eudragit RS.
- 5 18. The sustained release tablet formulation of claim 17, wherein the polymethacrylate is Eudragit RS 30 D.
19. The film coated sustained release tablet formulation of any of claims 1 to 18, wherein the coating solution includes 15-80% w/w Eudragit RS 30 D,
10 0.5-10% w/w titanium dioxide, 0.5-15% w/w talc, 0.5-10% w/w polyethylene glycol and 20-85% w/w purified water.
20. The film coated sustained release tablet formulation in claim 19, wherein the coating solution includes 30-70% w/w Eudragit RS 30 D, 1.5-6%
15 w/w titanium dioxide, 2-8% w/w talc, 1.5-5% w/w polyethylene glycol and 25-60% w/w purified water.
21. The film coated sustained release tablet formulation of claim 20 wherein the coating solution includes 45-60% w/w Eudragit RS 30 D, 2-3%
20 w/w titanium dioxide, 3.5-5% w/w talc, 1-3% w/w polyethylene glycol and 30-50% w/w purified water.
22. The film coated sustained release tablet formulation of claim 21 wherein the coating solution includes 52-54% w/w Eudragit RS 30 D, 2-3%
25 w/w titanium dioxide, 4-5% w/w talc, 1-3% w/w polyethylene glycol and 35-43% w/w purified water.
23. The film coated sustained release tablet formulation of any of claims 19 to 22, wherein the polyethylene glycol is Macrogol 6000.
30
24. The film coated sustained release tablet formulation of any of claims 1 to 22, wherein the amount of the film on the tablet is 0.5-3.0% w/w, preferably 1.0-2.0% w/w.

1/2

Fig. 1





Fig. 2



2/2

Fig. 3





Fig. 4



(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
19 August 2004 (19.08.2004)

PCT

(10) International Publication Number
WO 2004/069228 A3

(51) International Patent Classification⁷: **A61K 9/22**,
9/32, 31/137

(21) International Application Number:
PCT/IS2004/000003

(22) International Filing Date: 9 February 2004 (09.02.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
6710 7 February 2003 (07.02.2003) IS
7143 5 February 2004 (05.02.2004) IS

(71) Applicant (for all designated States except US): **OMEGA FARMA EHF.** [IS/IS]; Skutuvogi 1H, IS-104 Reykjavik (IS).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **JOHANNSSON**, Fjalar [IS/IS]; Hvassaleiti 14, IS-103 Reykjavik (IS). **ARNASON**, Birkir [IS/IS]; Kaplaskjolsvegi 85, IS-107 Reykjavik (IS).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,

GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declaration under Rule 4.17:

— of inventorship (Rule 4.17(iv)) for US only

Published:

— with international search report
— before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

(88) Date of publication of the international search report:
16 September 2004

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: SUSTAINED RELEASE FORMULATIONS OF VENLAFAXINE

(57) Abstract: The present invention relates to sustained release tablet formulations of venlafaxine. Kollidon SR proved to be an excellent sustained release agent for venlafaxine, that is an extremely soluble drug.

WO 2004/069228 A3

INTERNATIONAL SEARCH REPORT

International Application No
PCT/IS2004/000003

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 A61K9/22 A61K9/32 A61K31/137

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, BIOSIS, EMBASE, CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 94/27589 A (ALZA CORP) 8 December 1994 (1994-12-08) cited in the application examples 1,3 ----- -/--	1,5,6,14

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *Z* document member of the same patent family

Date of the actual completion of the international search

28 July 2004

Date of mailing of the international search report

09/08/2004

Name and mailing address of the ISA

European Patent Office, P.B. 5618 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Epskamp, S

INTERNATIONAL SEARCH REPORT

International Application No
PCT/IS2004/000003

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	MAKHIJA S N ET AL: "Once daily sustained release tablets of venlafaxine, a novel antidepressant" EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, ELSEVIER SCIENCE PUBLISHERS B.V., AMSTERDAM, NL, vol. 54, no. 1, July 2002 (2002-07), pages 9-15, XP004367686 ISSN: 0939-6411 cited in the application abstract paragraph '02.3! paragraph '0003! paragraph '0004!	1-24
Y	RUCHATZ F ET AL: "KOLLIDON SR - A NEW EXCIPIENT FOR SUSTAINED RELEASE MATRICES" PROCEEDINGS OF THE INTERNATIONAL SYMPOSIUM ON CONTROLLED RELEASE BIOACTIVE MATERIALS, vol. 26, 1999, pages 869-870, XP001119911 ISSN: 1022-0178 the whole document	1-24
A	EP 0 797 991 A (AMERICAN HOME PROD) 1 October 1997 (1997-10-01) page 2, line 39 - page 3, line 4 examples	1-24
P,X	WO 03/082262 A (PICHA FRANTISEK ; CUCALA ESCOI JOAN (ES); GALLEGU LUENGO MONTSERRAT (E) 9 October 2003 (2003-10-09) page 4, line 16 - line 24 page 28, line 12 - page 29, line 6 examples 6,7,9-11,13 claims	1,5,6, 11,12,14
P,X	US 2003/190354 A1 (SELA YORAM) 9 October 2003 (2003-10-09) examples claims paragraph '0018!	1,3-7, 11,13

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No
PCT/IS2004/000003

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 9427589	A	08-12-1994	US 6440457 B1	27-08-2002
			AU 677080 B2	10-04-1997
			AU 7048294 A	20-12-1994
			CA 2157186 A1	08-12-1994
			EP 0700289 A1	13-03-1996
			FI 955681 A	24-11-1995
			JP 8510755 T	12-11-1996
			NO 954694 A	24-11-1995
			NZ 267841 A	26-11-1996
			WO 9427589 A2	08-12-1994
			US 2004092601 A1	13-05-2004
			US 2004086570 A1	06-05-2004
			ZA 9403743 A	24-01-1995
EP 0797991	A	01-10-1997	AT 257011 T	15-01-2004
			AU 727653 B2	21-12-2000
			AU 1640097 A	02-10-1997
			BR 9701304 A	29-09-1998
			CA 2199778 A1	25-09-1997
			CN 1403077 A	19-03-2003
			CN 1164389 A , B	12-11-1997
			CZ 9700772 A3	12-11-1997
			DE 69727000 D1	05-02-2004
			DE 69727000 T2	09-06-2004
			DK 797991 T3	05-04-2004
			EP 1331003 A1	30-07-2003
			EP 0797991 A1	01-10-1997
			ES 2210454 T3	01-07-2004
			HU 9700589 A2	29-09-1997
			IL 120382 A	24-06-2003
			IN 187337 A1	30-03-2002
			JP 10007552 A	13-01-1998
			NO 971206 A	26-09-1997
			NZ 314442 A	29-06-1999
			PL 318954 A1	29-09-1997
			RU 2176912 C2	20-12-2001
			SI 797991 T1	30-04-2004
			SK 30197 A3	08-10-1997
			TR 9700190 A2	21-10-1997
			TW 493993 B	11-07-2002
			US 2002197307 A1	26-12-2002
			US 2003215507 A1	20-11-2003
			US 6274171 B1	14-08-2001
			US 2001055612 A1	27-12-2001
			US 2002025339 A1	28-02-2002
			ZA 9702403 A	21-09-1998
WO 03082262	A	09-10-2003	WO 03082262 A2	09-10-2003
			WO 03082806 A1	09-10-2003
			US 2003190352 A1	09-10-2003
			US 2003191347 A1	09-10-2003
US 2003190354	A1	09-10-2003	NONE	

